Találati lista | Tudóstér

001-es BibID:	BIBFORM105849
035-os BibID:	(cikkazonosító)1043275 (WOS)000904989100001 (Scopus)85145269011
Első szerző:	Viczján Gábor (kísérletes farmakológus)
Cím:	The effect of a long-term treatment with cannabidiol-rich hemp extract oil on the adenosinergic system of the Zucker Diabetic Fatty (ZDF) rat atrium / Viczjan Gabor, Szilagyi Anna, Takacs Barbara, Ovari Ignac, Szekeres Reka, Tarjanyi Vera, Erdei Tamas, Teleki Vanda, Zsuga Judit, Szilvassy Zoltan, Juhasz Bela, Varga Balazs, Gesztelyi Rudolf
Dátum:	2022
ISSN:	1663-9812
Megjegyzések:	Cannabidiol (CBD), the most extensively studied non-intoxicating phytocannabinoid, has been attracting a lot of interest worldwide owing to its numerous beneficial effects. The aim of this study was to explore the effect that CBD exerts on the adenosinergic system of paced left atria isolated from obese type Zucker Diabetic Fatty (ZDF) rats, maintained on diabetogenic rat chow, received 60 mg/kg/day CBD or vehicle via gavage for four weeks. We found that N6-cyclopentyladenosine (CPA), a relatively stable and poorly transported A1 adenosine receptor agonist, elicited a significantly weaker response in the CBD-treated group than in the vehicle-treated one. In contrast, adenosine, a quickly metabolized and transported adenosine receptor agonist, evoked a significantly stronger response in the CBD-treated group than in the vehicle-treated counterpart (excepting its highest concentrations). These results can be explained only with the adenosine transport inhibitory property of CBD (and not with its adenosine receptor agonist activity). If all the effects of CBD are attributed to the interstitial adenosine accumulation caused by CBD in the myocardium, then a significantly increased adenosinergic activation can be assumed during the long-term oral CBD treatment, suggesting a considerably enhanced adenosinergic protection in the heart. Considering that our results may have been influenced by A1 adenosine receptor downregulation due to the chronic interstitial adenosine accumulation, an adenosinergic activation smaller than it seemed cannot be excluded, but it was above the CBD-naïve level in every case. Additionally, this is the first study offering functional evidence about the adenosine transport inhibitory action of CBD in the myocardium.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk cannabidiol ZDF rat heart A1 adenosine receptor RRM
Megjelenés:	Frontiers in Pharmacology. - 13 (2022), p. 1-12. -
További szerzők:	Szilágyi Anna Tünde (1981-) Takács Barbara (1992-) (orvos) Óvári Ignác Szekeres Réka (1995-) (orvos) Tarjányi Vera (1993-) (orvos) Erdei Tamás Dániel (1992-) (kísérletes farmakológus) Teleki Vanda Zsuga Judit (1973-) (neurológus, pszichoterapeuta, egészségügyi szakmanager) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Juhász Béla (1978-) (kísérletes farmakológus) Varga Balázs (1984-) (kísérletes farmakológus) Gesztelyi Rudolf (1969-) (kísérletes farmakológus)
Pályázati támogatás:	GINOP-2.3.4-15-2020-00008 GINOP TKP2020-NKA-04 Egyéb
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM094881
035-os BibID:	(scopus)85105168586 (wos)000645572500001
Első szerző:	Wachal Zita
Cím:	Improved Survival and Retinal Function of Aging ZDF Rats in Long-Term, Uncontrolled Diabetes by BGP-15 Treatment / Zita Wachal, Anna Szilágyi, Barbara Takács, Adrienn Mónika Szabó, Dániel Priksz, Mariann Bombicz, Judit Szilvássy, Béla Juhász, Zoltán Szilvássy, Balázs Varga
Dátum:	2021
ISSN:	1663-9812
Megjegyzések:	Retinal complications of diabetes often lead to deterioration or even loss of vision. This hastens discovery of pharmacological agents able to counterbalance diabetic retinopathy. BGP-15, an emerging small molecule agent, was formerly proven by our workgroup to be retinoprotective on nonobese diabetic animals, Goto-Kakizaki rats. In the present study, we aimed to examine its long-term tolerability or incidental side effects on obese-prone Zucker diabetic fatty (ZDF) rats to further increase the rationale for a future human translation. To make terminal visual status comparable with our other investigations, we also carried out electroretinography (ERG) at the end of the experiment. Our study was started on 16-week-old ZDF rats and lasted for 52 weeks, while BGP was administered daily by gavage. During the 12 months of treatment, 100% of BGP-treated animals survived compared to the non-treated ZDF group, where 60% of the animals died, which was a statistically significant difference. Based on ERG results, BGP-15 was able to counterbalance visual deterioration of ZDF rats caused by long-term diabetes. Some moderate but significant changes were seen in OGTT results and some relationship to oxidative stress by the western blot method: BGP-15 was able to increase expression of HSP70 and decrease that of NFkB in eyes of rats. These were in concert with our previous observations of SIRT1 increment and MMP9 decrement in diabetic eyes by BGP. In summary, not only is BGP-15 not harmful in the long run but it is even able to reduce the related mortality and the serious consequences of diabetes. BGP-15 is an excellent candidate for future drug development against diabetic retinopathy.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk BGP-15 ERG ZDF diabetes retinopathy survival
Megjelenés:	Frontiers in Pharmacology. - 12 (2021), p. 1-11. -
További szerzők:	Szilágyi Anna Tünde (1981-) Takács Barbara (1992-) (orvos) Szabó Adrienn Mónika (1982-) (orvos) Priksz Dániel (1989-) (farmakológus) Bombicz Mariann (1987-) (gyógyszerész) Szilvássy Judit (1960-2022) (fül- orr- gégész) Juhász Béla (1978-) (kísérletes farmakológus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Varga Balázs (1984-) (kísérletes farmakológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: